前言 第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日至6日举行。本届ASCO年会MM领域者重磅研究有哪些呢，一起来看看吧。
摘要号：8010—MM-CAR-T
标题：Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
报告人：糜坚青
单位：上海交通大学医学院附属瑞金医院上海血液研究所、医学基因组学国家重点实验室
摘要号：8013-MM
标题：Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
报告人：Aimaz Afrough
单位：Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
摘要号：8017-MM
标题：Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma.
报告人：Mohammad Khan
单位：Emory University
摘要号：8020-MM
标题：Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
报告人：Paula Rodríguez-Otero
单位：Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA
摘要号：8029-MM
标题：Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
报告人：Khalid Shalaby
单位：Roswell Park Comprehensive Cancer Center
摘要号：8030-MM
标题：Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
报告人：Khalid Shalaby
单位：Roswell Park Comprehensive Cancer Center
摘要号：8036-MM
标题：Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
报告人：Carolina Schinke
单位：Myeloma Center, University of Arkansas for Medical Sciences
摘要号：8040—MM—药物疗效
标题：Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
报告人：Noopur Raje
单位：Massachusetts General Hospital Cancer Center, Harvard Medical School
摘要号：8041—MM—给药
标题：Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
报告人：Xuewen Ma
单位：Janssen Research & Development
摘要号：TPS8063
标题：A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
报告人：Jesus Berdeja
单位：Sarah Cannon Research Institute
摘要号：TPS8068—新药--MM
标题：OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
报告人：Dagmar Hess
单位：Kantonsspital St. Gallen
摘要号：TPS8070--MM
标题：A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
报告人：Paul Richardson
单位：Dana-Farber Cancer Institute
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
学习起来
41